Physician-assisted doping of athletes has transformed high-performance sport into a chronically overmedicated subculture and spread so-called hormonal rejuvenation to the general public.
Distinctions between treatment and enhancement, and between supposedly authentic and inauthentic tools, often inform judgments about what is morally acceptable in sport.
David Elkin, MD, Erick Hung, MD, and Gilbert Villela, MD
The rapidly evolving field of neuroethics is concerned with the ethical questions that new technologies will pose about autonomy, privacy, the definition of normal, and individuality.
Reporting of post-CABG mortality rates has resulted in a decrease in in-hospital mortality, and non-outcome-based measures of care quality show promise of improving patient satisfaction.
AMA J Ethics. 2015;17(7):647-650. doi:
10.1001/journalofethics.2015.17.7.stas2-1507.
This month, AMA Journal of Ethics theme editor Jacquelyn Nestor, a fifth-year MD/PhD student at Hofstra-Northwell School of Medicine, interviewed Allen Buchanan, PhD, about how we can safely explore cutting-edge biomedical enhancements.
This month theme issue editor, Trahern Jones, a fourth-year student at Mayo Medical School in Rochester, Minnesota, spoke with Dr. Edward Laskowski about the use of performance-enhancing drugs and substances among athletes today.
The belief persists that patient satisfaction surveys are more responsive to friendliness and expensive facilities than clinician interaction, but there is evidence to the contrary.
Concerns about the deleterious effects of stress on the mind and body have led to the beginnings of a stress vaccine, an injection that will reduce these effects.